After 24 weeks of treatment in this study, the H-FABP, vWF, and NO values in both groups decreased; the valsartan group decreased more significantly, while the foot-and-mouth disease and NMD in both groups increased; and the valsartan group increased. This evidence concerns the gene FABP3 and foot and mouth disease.